Patent 9051365 was granted and assigned to Novartis on June, 2015 by the United States Patent and Trademark Office.
The present invention relates to antibodies or antigen binding fragments thereof that bind to complement Factor P and used thereof as well as combinations of anti-Factor P antibodies with antibodies or antigen binding fragments thereof that bind to complement component 5 (C5).